Drug intelligence / Profile preview

MB-1801

Development stage: Preclinical
Lead developer: Mainline Biosciences
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules

Overview

MB-1801 is a peptide-drug conjugate developed by Mainline Biosciences. It functions as a modulator of HER2 (Receptor tyrosine-protein kinase erbB-2), targeting this receptor for potential therapeutic benefit. The drug is being investigated primarily for the treatment of brain metastases and other neoplasms, with additional interest in nervous system diseases. As of June 2025, its highest development status is preclinical[1].

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on MB-1801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-1801.

Explore the full profile